On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Financial Comparison: Who Is Winning?
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC’s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN’s mature products.
Bull and Bear Cases
Amgen’s bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline assets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
AstraZeneca’s bull case rests on its strength in oncology and rare diseases, which continues to support high-margin growth, while more than 20 late-stage readouts planned over the next 18 months could help maintain its trajectory toward the $80 billion 2030 revenue target. On the downside, weakness in its CVRM segment, which declined 8% in H1 amid Farxiga’s U.S. patent loss and pricing pressures in China, could weigh on regional and overall top-line growth.
Insider Monkey’s Hedge Fund Data Analysis
Hedge fund positioning reflects diverging institutional conviction. Amgen saw a slight uptick in support during Q2 2026, held by 66 funds (up from 65 in Q1). Key holders include Ken Fisher’s Fisher Asset Management (1.59 million shares valued at $575.6 million) and D. E. Shaw (1.29 million shares valued at $467.2 million after a 625% position increase).
Conversely, AstraZeneca lost modest institutional backing, dropping from 56 to 55 funds in Q2, with notable managers like Joel Greenblatt’s Gotham Asset Management and Hari Hariharan’s NWI Management holding zero shares.
Conclusion & What to Watch Next
Both companies demonstrate strong pipeline execution, but investors should monitor distinct upcoming catalysts. For Amgen Inc., track detailed Phase 3 data for olpasiran to clarify its cardiovascular positioning alongside Repatha’s expanded mortality case, while watching how effectively new product launches offset Prolia biosimilar erosion. For AstraZeneca PLC, monitor late-stage oncology readouts and foreign exchange shifts as it works toward its $80 billion 2030 revenue milestone.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
